New hope for tiny tummies: drug trial targets deadly infant gut disease
NCT ID NCT06315738
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called ST266 in premature infants with necrotizing enterocolitis (NEC), a severe gut infection. The trial will include 36 babies and aims to see if the drug is safe and tolerable at two different doses. Researchers will also look for early signs that it helps the gut heal faster.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ST266 (a biologic drug made from cells)
What this could lead to
If it works, this could point toward a new treatment for necrotizing enterocolitis, a life-threatening gut condition in premature infants.
What could go wrong
This is an early phase 1-2 trial with only 36 infants, so it is primarily testing safety. The drug may not prove effective, and there could be unknown side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NECROTIZING ENTEROCOLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Arkansas Children's Hospital
RECRUITINGLittle Rock, Arkansas, 72202, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
BayCare Health System-St. Joseph's Women's Hospital
RECRUITINGTampa, Florida, 33607, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
NorthShore University-Evanston Hospital
RECRUITINGEvanston, Illinois, 60201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
-
Oklahoma Children's Hospital
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Penn State Health Milton S Hershey Medical Center/Penn State University College of Medicine
RECRUITINGHershey, Pennsylvania, 17033, United States
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Arkansas for Medical Sciences
RECRUITINGLittle Rock, Arkansas, 72205, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Pittsburgh Medical Center Magee Womens Hospital
RECRUITINGPittsburgh, Pennsylvania, 15219, United States
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Yale-New Haven Hospital
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact